Paulo Luz: AI for Patients with HER2+ Breast Cancer – HER2pCRPredict

Paulo Luz shared a post on LinkedIn:

”AI for Patients with HER2+ Breast Cancer – HER2pCRPredict.

During my PhD research at Lusophone University – Lisbon University Center, CBIOS – Research Center for Biosciences and Health Technologies we developed a comprehensive dataset of patients with HER2+ breast cancer to explore predictive factors for pathologic complete response (pCR) and relapse. In collaboration with Spaik Technologies, we utilized machine learning to create an online calculator, HER2pCRPredict, designed to assist doctors in predicting the likelihood of pCR following neoadjuvant treatment with chemotherapy, trastuzumab, and pertuzumab.

Our goal is to enhance clinical decision-making by providing a reliable resource for managing HER2+ breast cancer, ultimately leading to more precise and effective treatment strategies.

The paper detailing this development will be published soon. We are also looking to validate this tool across different cohorts. If you have a dataset of HER2+ breast cancer patients who received trastuzumab and pertuzumab as neoadjuvant treatment, your contribution would be invaluable in improving the HER2pCRPredict tool.

Please get in touch through LinkedIn or via email at [email protected].

A special thanks to Enrique Álvarez Robles and Spaik Technologies for their assistance in developing this tool.”

Source: Paulo Luz/LinkedIn

Paulo Luz is a medical oncologist at University Hospital Center of the Algarve in Faro, Portugal. He is also affiliated with the Research Center for Biosciences and Health Technologies at Lusophone University in Lisbon. His work primarily focuses on oncology, with involvement in both clinical practice and research, especially in the areas of palliative care and cancer management.